Minerva Neurosciences (NERV)

• Market cap: $15.2M
• 1 day: 2.35%
• 5 days: -5.63%
• 1 month: 23.86%
• 3 months: 21.79%
• 6 months: 29.76%
• Year to date: -5.22%
• 1 year: -20.73%
• 5 years: -91.96%
• 10 years: -95.29%
• Sector: Healthcare
• Industry: Biotechnology

About: Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.

Employees: 8

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

1% more capital invested

Capital invested by funds: $3.31M [Q1] → $3.34M (+$31.8K) [Q2]

0.12% less ownership

Funds ownership: 27.93% [Q1] → 27.81% (-0.12%) [Q2]

5% less funds holding

Funds holding: 22 [Q1] → 21 (-1) [Q2]

20% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 5

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4